These observations might indicate that loss of cell cycle control characterised by a complete lack of p16INK4a expression defines a relatively small, but distinct subgroup of advanced-stage ovarian cancer patients with an unfavourable prognosis. The gene discussed is CDKN2A; the disease is ovarian carcinoma.